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Description

Thrombotic thrombocytopenic purpura (TTP) is a rare, potentially life-threatening disorder
characterized by uncontrolled and spontaneous clot formation throughout the body. Known
secondary causes of TTP include malignancy, bone marrow transplantation, pregnancy,
various medications, and HIV infection. TTP in the setting of COVID-19 vaccination is rare
and not well reported. Reported cases have been confined primarily to the AstraZeneca and
Johnson and Johnson COVID-19 Vaccines. TTP in the setting of Pfizer BNT-162b2 vaccination
has only recently been reported. We present a patient with no obvious risk factors for TTP
who presented with acute altered mental status and was found to have objective evidence
of TTP. To our knowledge, there are very few reported cases of TTP in the setting of a recent
Pfizer COVID-19 vaccination.
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Introduction

The United States (US) Food and Drug Administration (FDA) issued an emergency use
authorization (EUA) of the Pfizer COVID-19
vaccine for individuals ages 16 years or older,
on December 11, 2020.1 The age bracket was
later extended to include children from 5-15
years of age under the EUA.2 This was the first
marketed vaccine in the US for the prevention
of SARS-CoV-21 and as of now, more than 75%
of US adults have received at least a single
shot of one of the three authorized COVID-19
vaccines.3 To date, over 200 million Pfizer BNT162b2 vaccinations have been administered
worldwide. As one of the first vaccinations
to obtain FDA approval in the US, this mRNA
vaccine has an important role in the prevention and mitigation of the COVID-19 pandemic.
Since the beginning of the pandemic, a pleth-

ora of research and case reports have been
published regarding additional specific adverse
effects of various COVID-19 vaccines. In preliminary studies, the most common serious adverse events reported were appendicitis, acute
myocardial infarction, and cerebrovascular accident which are found to have a higher incidence
in the vaccination groups versus the placebo
group, with the overall incidence being 0.6% of
patients in the vaccination group.4 Thrombotic
thrombocytopenic purpura (TTP) was reported
as a consequence of COVID-19 infection itself5,
but recent reports suggest that TTP may be
associated with recent Pfizer vaccine administration.6-9 Phenomena of thrombocytopenia
with thrombotic events of possible vaccine-induced thrombotic thrombocytopenia (VITT)
were reportedly associated with the Johnson
and Johnson and AstraZeneca vaccines, which
are not BNT-162b2 vaccines.10 Presentation of
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Figure 1. An image of a peripheral smear indicates florid schistocytes (some highlighted with
black arrows), nucleated red blood cells, and rouleaux formations (40X magnification).
TTP can involve a pentad of findings of fever,
microangiopathic hemolytic anemia (MAHA)
with schistocyte formation, thrombocytopenia,
renal dysfunction, and changes in mental status, although the presence of all 5 symptoms
overall is quite rare.8 To our knowledge, this is
one of very few reported cases of BNT-162b2
vaccine-associated TTP worldwide.

Case Presentation

We present a case of a 75-year-old male of
Indian descent with a past medical history of
hypertension and diabetes mellitus who presented to the hospital with a complaint of
altered mental status, associated with difficulty speaking since the morning on the day
of presentation. The patient was otherwise in
good health with no active complaints until the
morning of the presentation. His home medications included losartan, glimepiride, metformin, and sitagliptin. There was no reported
history of any recent sick contacts or exposure
to someone who tested positive for COVID-19,
recent travel, changes in home medication,
substance abuse, history of trauma, or any recent hospitalization. The patient was, however,
administered his second dose of the BNT-162b2
vaccine 23 days prior to the current presentation. On admission, a stroke alert was called
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out of concern from the endorsed symptoms.
Initial vital signs were stable. A preliminary neurological exam was notable for mild dysarthria,
slurred speech, and slight right lower extremity
drift. Computerized tomography (CT) of the
head and CT angiogram (CTA) of the head and
neck were negative for intracranial hemorrhage, large vessel occlusion, or any other acute
findings. The patient was outside the window
for tissue plasminogen activator therapy and
subsequently was admitted for further management.
Initial blood work showed hemoglobin of 8.1 g/
dL (reference range: 12-17 g/dL), platelets of
18 x 109/L (reference range: 150-400 x 109/L),
aspartate transaminase (AST) of 255 U/L
(reference range: <37 U/L), alanine transaminase (ALT) of 222 U/L (reference range: <78
U/L), prothrombin time of 14.5 sec (reference
range: 10.2-12.9 sec), and lactate dehydrogenase
(LDH) was 2356 U/L (reference range: 85-227
U/L). Blood peripheral smear was evident for
schistocytes (Figure 1). Our working diagnosis was TTP, as there was a clinical concern of
MAHA and acquired thrombocytopenia with a
plasmic score of 6. During the placement of a
non-tunneled dialysis catheter for emergent
plasma exchange, the patient had generalized
seizure-like activity with a subsequent worsen-
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Figure 2. The trend of platelet count during the patient’s hospital course (Normal platelet range:
150-400 x 109/L) is shown. The initiation of plasma exchange and steroids (blue arrow), rituximab
(orange arrow), and IVIG (yellow arrow) are indicated.
ing of mentation, requiring intubation to secure
the airway.
After multidisciplinary consultation, it was
determined that the patient was to undergo
daily plasma exchange and to start a pulse
dose of intravenous (IV) methylprednisolone
1g daily. Meanwhile, a serological workup was
ordered including, ADAMTS13 (a disintegrin and
metalloprotease with a thrombospondin type
1 motif, member 13) antibody and activity level,
HIV antibodies, serum protein electrophoresis,
antinuclear antibody, rapid plasma reagin, PF-4
(platelet factor-4/heparin-induced thrombocytopenia [HIT]) autoantibodies, antinuclear
nuclear antibody titers, and hepatitis screening
along with non-contrast magnetic resonance
imaging (MRI) of the brain, CTA of the chest,
an echocardiogram and a liver ultrasound.
These laboratory and radiological studies were
ordered to rule out other potential etiologies
of the patient’s clinical presentation and to
look for objective evidence of thrombosis. The
patient continued on daily plasma exchange
and pulse dose IV steroids with no clinical improvement, and platelets remained essentially
unchanged, staying stable around 19-20 x 109/L.
For his refractory clinical response to the treatment, the differential diagnosis was broadened

further, to include concurrent idiopathic thrombotic purpura, and the decision was made to
start IV immunoglobulin (IVIG) on day 4. Concurrently, rituximab was also started on day 4
and his platelet count started improving to 50 x
109/L, on day 5 of hospitalization (Figure 2).
The blood workup returned as negative, except
for elevated ADAMTS13 antibody titer (>182 U/
ml, reference range: <12 U/ml) and ADAMTS13
activity level of less than 2% (reference range:
> 66.8%), confirming the diagnosis of TTP. An
MRI of the brain (Figure 3) showed bilateral
cerebral and cerebellar hemispheres infarcts,
likely secondary in the setting of TTP thrombosis, although the chest CTA remained negative
for pulmonary embolism, the echocardiogram
read as normal biventricular function with no
evidence of wall motion abnormality or intracardiac thrombus, and the liver ultrasound
showed normal main portal vein flow. The
patient was eventually able to tolerate spontaneous breathing trials and was finally weaned
from the ventilator. Plasma exchange was
reduced in frequency from daily to every other
day and eventually to every 72 hours. Initial IV
methylprednisolone was tapered to oral prednisone. Prophylactic trimethoprim/sulfamethoxazole was started given his prolonged high

345

HCA Healthcare Journal of Medicine

A

B

C

Figure 3. A magnetic resonance diffusion-weighted axial image shows multiple small foci scattered throughout both cerebral (white arrows in A and B) and cerebellar (white arrow in C) hemispheres indicating scattered punctate acute infarctions.
dose steroid use. In total, he received 4 doses
of rituximab (375 mg/m2 once weekly infusions) and IVIG. He was finally discharged to an
inpatient rehabilitation center, where he stayed
for 14 days and was discharged home after the
removal of the temporary dialysis catheter. To
ensure the stability of his platelet count, it was
monitored through the course of the patient’s
stay and was reported as 170 x 109/L on the
day of discharge from the hospital and as 219 x
109/L on the day of discharge from the rehabilitation center. His platelet count was found to
be within the normal range on his most recent
outpatient visit, 6 months following the discharge from the rehabilitation center.

Discussion

TTP is a rare, life-threatening disorder associated with thrombocytopenia, microangiopathic
hemolytic anemia, and thrombotic events secondary to underlying inherited or acquired deficiency of von-Willebrand factor (vWF)-cleaving
protease ADAMTS13. The severely reduced
ADAMTS13 activity (generally less than 10%)
leads to ultra-large multimers of vWF because
of its insufficient processing. This larger molecular structure gets disheveled while passing
through the microcirculation system, where it
triggers unwanted aggregation of platelets,
and finally a thrombosis.11,12 Prompt recognition
and empiric treatment are crucial, as TTP is almost always fatal if not treated. Treatment focuses on plasma exchange, which removes the
vWF-multimer complexes from the circulation.
Other concurrent strategies used include high-
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dose IV steroids and rituximab. With timely
diagnosis and appropriate treatment, survival
rates range anywhere from 60 to 90%. TTP is
predominantly found in females and those of
African descent and the median age of presentation is typically around 40 years. It is unusual
for TTP to present in the elderly, especially over
the age of 70 years; this case was unusual as
the patient was a male, 75 years of age, and
of Indian descent.9 Congenital TTP is typically
caused by autoantibodies or a mutation against
ADAMTS13. Acquired TTP often occurs in the
setting of concurrent organ transplantation,
malignancy, pregnancy, autoimmune diseases (especially systemic lupus erythematosus
[SLE])8,9, or medications, such as mitomycin C,
quinine, cyclosporine, ticlodipine, or clopidogeral, among others.8,9,13 Our patient had none of
these risk factors, and the workup for other
causes was negative.
The BNT-162b2 vaccine was the first FDA-approved vaccine for the prevention of SARSCov-2. It was initially targeted for individuals
ages 16 years and older, to be administered in
2 doses 21 days apart, and is now authorized,
through EUA for ages 5 years and over.2 Recently, the FDA recommended a third (booster
dose) for ages 12 years and older, at least 5
months after completion of the primary BNT162b2 vaccine series.2 The most common reported side effects include pain at the injection
site, myalgias, headache, fevers, and nausea.4
Previously known safety concerns with the use
of mRNA vaccines include: local, or systemic
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inflammatory responses,12,14 and the possibility
of thrombus formation, potentially because
mRNA causes platelet-independent direct
activation of coagulation factors. The same
hypothesis was extended as a probable cause
for thromboembolic events in cancer patients.
mRNA vaccines induce immune complexes
containing RNA-binding proteins, triggering
plasmacytoid dendritic cells via toll-like receptors (TLR), leading to an elevation in serum
type-1 interferon (IFN) immune activity.11 The
type-1 IFN system, which plays an important
role in innate and adaptive immunity, is associated with the production of autoantibodies against RNA-binding proteins16 in various
autoimmune diseases including SLE. Drug17 and
inflammation-induced18 type-1 IFN responses
are also well-documented triggers for thrombotic microangiopathy17, including TTP due to
the acquired deficiency of ADAMTS13.11
Further reports have been published depicting
more uncommon side effects of the vaccines
for COVID-19. Preliminary studies suggested evidence of a vaccine-induced thrombotic
thrombocytopenia (VITT) following Astra-Zeneca and Johnson and Johnson vaccination,
which are not mRNA vaccines.10,19 The diagnostic criteria for VITT include the evidence of
COVID-19 vaccination within the last 4 to 42
days, any thrombotic event, platelet count <
150 x 109/L, positive PF4 (HIT) assay, and D-dimer of greater than 4 times the upper normal
limit.10 In the present case, the HIT assay was
negative, and therefore we assumed VITT was a
less likely mechanism in our patient. Moreover,
the patient’s lack of clinical improvement raised
a possible concern for autoimmune hemolysis
with concomitant immune-thrombocytopenia
and the decision was made to start IVIG on day
6 of hospitalization. Although IVIG was also
used as an adjuvant therapy, in TTP refractory
to plasma exchange, its first-line use has not
been thoroughly established.20
The pathophysiology of vaccine-induced TTP
is not well understood. The first case report
on vaccine-induced TTP was published in 1960,
involving the typhoid vaccine. Since then,
there have been other reported cases involving
influenza, pneumococcal, and H1N1 vaccines
among others.5,6 It is thought to potentially
occur through proposed mechanisms such as
increased vWF-release from the endothelium7

or due to molecular mimicry from vaccine antigens.9 Further studies are needed to confirm
these hypotheses.

Conclusion

TTP is a life-threatening disorder that needs to
be treated emergently with plasma exchange
while awaiting further test results. With the
increased administration of COVID-19 vaccinations, more serious side effects are being
reported. In the present case, as there was no
objective evidence for concurrent infection,
immunocompromised conditions, a genetic
component, an autoimmune process, or malignancy, we believe the recently administered
Pfizer BNT-162b2 vaccination presented the
most likely cause of his diagnosis. TTP is a rare
side effect, with only 5 reported cases globally
in the setting of the recent Pfizer BNT-162b2
vaccination.6-9,21 Therapy relies upon plasma exchange, with further mitigation from steroids
and potentially rituximab. IVIG may be used as
an adjuvant to enhance clinical success however, its role in the first episode of TTP has yet
to be established. Through this case report we
hope to bring greater awareness to TTP as a
significant potential complication of COVID-19
vaccination, in particular the Pfizer BNT-162b2
vaccine. With further clinical and laboratory
research, this association can be better understood.

Conflicts of Interest

The authors declare that they have no conflicts
of interest.
The authors are employees of HCA Florida
Orange Park Hospital, a hospital affiliated with
the journal’s publisher.
This research was supported (in whole or in
part) by HCA Healthcare and/or an
HCA Healthcare affiliated entity. The views
expressed in this publication represent those of
the author(s) and do not necessarily represent
the official views of HCA Healthcare or any of
its affiliated entities.
1.

Author Affiliations

HCA Florida Orange Park Hospital, Orange
Park, FL

347

HCA Healthcare Journal of Medicine

References
1.

2.
3.

4.
5.

6.

7.

8.

9.

10.

11.

348

US Food and Drug Administration. PfizerBioNTech COVID-19 Vaccines: Comirnaty
and Pfizer-BioNTech COVID-19 Vaccine.
2021. https://www.fda.gov/emergencypreparedness-and-response/coronavirusdisease-2019-covid-19/pfizer-biontechcovid-19-vaccines
COMIRNATY® (COVID‑19 Vaccine, mRNA).
Pfizer; 2022. https://www.comirnaty.com/
United States Census Bureau. Household
Pulse Survey COVID-19 Vaccination
Tracker. December 22, 2021. https://
www.census.gov/library/visualizations/
interactive/household-pulse-surveycovid-19-vaccination-tracker.html
Pfizer-BioNTech COVID-19 Vaccine
Overview and Safety (also known as
COMIRNATY). 2021.
Karabulut K, Andronikashvili A,
Kapici AH. Recurrence of thrombotic
thrombocytopenic purpura after mRNA1273 COVID-19 vaccine administered
shortly after COVID-19. Case Rep Hematol.
2021;2021:4130138. doi:10.1155/2021/4130138
de Bruijn S, Maes MB, De Waele L,
Vanhoorelbeke K, Gadisseur A. First
report of a de novo iTTP episode
associated with an mRNA-based antiCOVID-19 vaccination. J Thromb Haemost.
2021;19(8):2014-2018. doi:10.1111/jth.15418
Ruhe J, Schnetzke U, Kentouche K, et al.
Acquired thrombotic thrombocytopenic
purpura after first vaccination dose of
BNT162b2 mRNA COVID-19 vaccine. Ann
Hematol. 2022;101(3):717-719. doi:10.1007/
s00277-021-04584-y
Waqar SHB, Khan AA, Memon S.
Thrombotic thrombocytopenic purpura:
a new menace after COVID bnt162b2
vaccine. Int J Hematol. 2021;114(5):626629. doi:10.1007/s12185-021-03190-y
Chamarti K, Dar K, Reddy A, Gundlapalli
A, Mourning D, Bajaj K. Thrombotic
thrombocytopenic purpura presentation
in an elderly gentleman following
COVID vaccine circumstances. Cureus.
2021;13(7):e16619.
Bussel JB, Connors JM, Cines DB, et
al. Thrombosis with Thrombocytopenia
Syndrome (also termed Vaccine-induced
Thrombotic Thrombocytopenia) 2021. Last
updated: January 28, 2022 https://www.
hematology.org/covid-19/vaccine-inducedimmune-thrombotic-thrombocytopenia
Edgar CE, Terrell DR, Vesely SK, et al.
Ribosomal and immune transcripts
associate with relapse in acquired
ADAMTS13-deficient thrombotic
thrombocytopenic purpura. PLoS One.

12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

2015;10(2):e0117614. doi:10.1371/journal.
pone.0117614
Pardi N, Hogan MJ, Porter FW,
Weissman D. mRNA vaccines - a new
era in vaccinology. Nat Rev Drug Discov.
2018;17(4):261-279. doi:10.1038/nrd.2017.243
Medina PJ, Sipols JM, George JN. Drugassociated thrombotic thrombocytopenic
purpura-hemolytic uremic syndrome.
Curr Opin Hematol. 2001;8(5):286-293.
doi:10.1097/00062752-200109000-00004
Pepini T, Pulichino AM, Carsillo T, et al.
Induction of an IFN-mediated antiviral
response by a self-amplifying RNA
vaccine: implications for vaccine design.
J Immunol. 2017;198(10):4012-4024.
doi:10.4049/jimmunol.1601877
Kannemeier C, Shibamiya A, Nakazawa
F, et al. Extracellular RNA constitutes a
natural procoagulant cofactor in blood
coagulation. Proc Natl Acad Sci U S A.
2007;104(15):6388-6393. doi:10.1073/
pnas.0608647104
Niewold TB, Hua J, Lehman TJ, Harley
JB, Crow MK. High serum IFN-alpha
activity is a heritable risk factor for
systemic lupus erythematosus. Genes
Immun. 2007;8(6):492-502. doi:10.1038/
sj.gene.6364408
Pisoni R, Ruggenenti P, Remuzzi G. Druginduced thrombotic microangiopathy:
incidence, prevention and management.
Drug Saf. 2001;24(7):491-501.
doi:10.2165/00002018-200124070-00002
Swisher KK, Doan JT, Vesely SK, et al.
Pancreatitis preceding acute episodes of
thrombotic thrombocytopenic purpurahemolytic uremic syndrome: report of
five patients with a systematic review
of published reports. Haematologica.
2007;92(7):936-943. doi:10.3324/
haematol.10963
Greinacher A, Langer F, Makris M, et al.
Vaccine-induced immune thrombotic
thrombocytopenia (VITT): update on
diagnosis and management considering
different resources. J Thromb Haemost.
2022;20(1):149-156. doi:10.1111/jth.15572
Ding J, Baer MR, Hess JR, Zimrin AB.
Intravenous immunoglobulin as salvage
therapy for refractory thrombotic
thrombocytopenic purpura. Am J
Hematol. 2018;93(3):E77-E79. doi:10.1002/
ajh.25007
Jasaraj RB, Shrestha DB, Gaire S, Kassem
M. Immune thrombocytopenic purpura
following Pfizer-BioNTech COVID-19
vaccine in an elderly female. Cureus.
2021;13(8):e16871. doi:10.7759/cureus.16871

